1stOncology™: Cancer Intelligence Service – Page 14366 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Clovis Oncology Announces Second U.S. Patent Issued in Rucaparib High Dosage Strength Tablet Patent Family with Expiration in 2035

On November 20, 2018 Clovis Oncology, Inc. (NASDAQ:CLVS) reported that the United States Patent and Trademark Office issued United States Patent 10,130,636 with claims directed to methods of treating cancer with high dosage strength rucaparib camsylate formulations (Press release, Clovis Oncology, NOV 20, 2018, View Source [SID1234531510]). The patent claims cover methods of treating cancer with commercial Rubraca product, including all commercial dosage strengths (200, 250 and 300mg). The high dosage strength rucaparib formulation patent expires in 2035, and will join multiple patents directed to rucaparib, rucaparib camsylate, and methods of treatment as the 11th Orange Book-listed patent for rucaparib.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

"We have multiple families of patents protecting Rubraca in the U.S., including composition of matter, salts/polymorphs, dosage forms and formulations, and methods of use, and we continue to add new patents, including this high dosage strength method of treatment patent," said Patrick J. Mahaffy, President and CEO of Clovis Oncology. "Each additional patent provides further protection for Rubraca, and this is relevant not only to our current indications in ovarian cancer, but also to multiple potential additional indications based on our ongoing and substantial clinical development programs."

About Rubraca (rucaparib)

Rubraca is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in multiple tumor types, including ovarian, metastatic castration-resistant prostate, and bladder cancers, as monotherapy, and in combination with other anti-cancer agents. Exploratory studies in other tumor types are also underway. Clovis holds worldwide rights for Rubraca. Rubraca is an unlicensed medical product outside of the U.S. and Europe.

Syros to Present at 30th Annual Piper Jaffray Healthcare Conference

On November 20, 2018 Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, reported that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the 30th Annual Piper Jaffray Healthcare Conference (Press release, Syros Pharmaceuticals, NOV 20, 2018, View Source [SID1234531509]). Details are as follows:

30th Annual Piper Jaffray Healthcare Conference
Date: Tuesday, November 27
Presentation Time: 4:30 p.m. ET
Location: Lotte New York Palace, 455 Madison Avenue, New York, NY

A live webcast of the presentation will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay will be available for approximately 30 days following the fireside chat

AVEO Oncology to Present at the 30th Annual Piper Jaffray Healthcare Conference

On November 20, 2018 AVEO Oncology (NASDAQ:AVEO) reported that Michael Bailey, president and chief executive officer, will present at the 30th Annual Piper Jaffray Healthcare Conference in New York on Wednesday, November 28, 2018 at 2:30 p.m. Eastern Time (Press release, AVEO, NOV 20, 2018, View Source [SID1234531508]). The conference is being held at the Lotte New York Palace Hotel.

A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following the presentation date.

Deciphera Pharmaceuticals, Inc. to Present at the 30th Annual Piper Jaffray Healthcare Conference

On November 20, 2018 Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, reported that Michael D. Taylor, Ph.D., President and Chief Executive Officer, will present at the 30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27, 2018 at 2:30 PM ET at the Lotte New York Palace Hotel (Press release, Deciphera Pharmaceuticals, NOV 20, 2018, View Source [SID1234531505]).

A live webcast of the event will be available on the "Events and Presentations" page in the "Investors" section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

Curis to Present at the 60th Annual Meeting of the American Society of Hematology

On November 20, 2018 Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, reported three upcoming poster presentations at the 60th annual meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper) (Press release, Curis, NOV 20, 2018, View Source [SID1234531504]). Curis’s poster presentations will be available for viewing on Monday, December 3 (Session III) from 10 a.m. to 8 p.m. PT with presentations from 6 p.m. to 8 p.m. PT in Hall GH at the San Diego Convention Center.

Curis will present three posters at the ASH (Free ASH Whitepaper) conference providing key information supporting development of fimepinostat in patients with DLBCL, including patients with MYC-alterations, and CA-4948, Curis’s IRAK4 inhibitor, for patients with lymphomas. A pooled analysis of R/R DLBCL patients treated with fimepinostat demonstrates adequate safety and anti-tumor activity supporting the biologic rationale for continued development of fimepinostat in this patient population. Additionally, Curis will present preclinical data and biological rationale that support CA-4948 development in patients with tumors sensitive to the IRAK4 signaling pathway as well as data supporting the potential for IRAK4-based combination regimens to overcome drug tolerance in patients with Non-Hodgkin Lymphoma.

Details of these presentations are as follows:

Curis Presentations at American Society of Hematology (ASH) (Free ASH Whitepaper) 60th Annual Meeting

Viewing Date/Time:

Monday, Dec. 3, 10:00 AM – 8:00 PM PT

Presentation Date/Time:

Monday, Dec. 3, 6:00 PM – 8:00 PM PT

Location:

Hall GH, San Diego Convention Center

Abstract Number:

4168

Presentation Title:

Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination with Targeted Therapies and Preliminary Phase 1 Clinical Results in Non-Hodgkin Lymphoma

Abstract Number:

4184

Presentation Title:

A Pooled Analysis of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients Treated with the Dual PI3K and HDAC Inhibitor Fimepinostat (CUDC-907), Including Patients with MYC-Altered Disease

Abstract Number:

2649

Presentation Title:

Drug Combinations Co-Targeting Myeloid Cell Leukemia-1 (Mcl-1) Protein Can Overcome Microenvironmentally-Induced Multi-Drug Tolerance in Non-Hodgkin Lymphomas